Abstract
One-third of the worlds population is infected with Mycobacterium (M.) tuberculosis. Tuberculosis continues to be the most common infectious cause of death and still has a serious impact, medically, socially and financially. Multidrug-resistant tuberculosis (MDR-TB), caused by tubercle bacilli that are resistant to at least isoniazid and rifampin, is among the most worrisome elements of the pandemic of antibiotic resistance because TB patients for whom treatment has failed have a high risk of death. Drugs used to treat tuberculosis are classified into first-line and second-line agents. First-line essential anti-tuberculosis agents are the most effective, and are a necessary component of any short-course therapeutic regimen. The drugs in this category are isoniazid, rifampin, ethambutol, pyrazinamide and streptomycin. Second-line anti-tuberculosis drugs are clinically much less effective than first-line agents and elicit severe reactions much more frequently. These drugs include para-aminosalicylic acid (PAS), ethionamide, cycloserine, amikacin and capreomycin. New drugs, which are yet to be assigned to the above categories, include rifapentine, levofloxacin, gatifloxacin and moxifloxacin. Recently there has been much development in the molecular pharmacology of anti-tuberculosis drugs. This review summarizes information for isoniazid, rifampicin, ethambutol, pyrazinamide, and fluoroquinolones, and describes their resistance mechanisms.
Keywords: Isoniazid, Mycobacterium tuberculosis, Rifamycins, embCAB gene, Pyrazinoic acid
Mini-Reviews in Medicinal Chemistry
Title: Overview of Anti-Tuberculosis (TB) Drugs and Their Resistance Mechanisms
Volume: 7 Issue: 11
Author(s): Ruiru Shi, Nobunori Itagaki and Isamu Sugawara
Affiliation:
Keywords: Isoniazid, Mycobacterium tuberculosis, Rifamycins, embCAB gene, Pyrazinoic acid
Abstract: One-third of the worlds population is infected with Mycobacterium (M.) tuberculosis. Tuberculosis continues to be the most common infectious cause of death and still has a serious impact, medically, socially and financially. Multidrug-resistant tuberculosis (MDR-TB), caused by tubercle bacilli that are resistant to at least isoniazid and rifampin, is among the most worrisome elements of the pandemic of antibiotic resistance because TB patients for whom treatment has failed have a high risk of death. Drugs used to treat tuberculosis are classified into first-line and second-line agents. First-line essential anti-tuberculosis agents are the most effective, and are a necessary component of any short-course therapeutic regimen. The drugs in this category are isoniazid, rifampin, ethambutol, pyrazinamide and streptomycin. Second-line anti-tuberculosis drugs are clinically much less effective than first-line agents and elicit severe reactions much more frequently. These drugs include para-aminosalicylic acid (PAS), ethionamide, cycloserine, amikacin and capreomycin. New drugs, which are yet to be assigned to the above categories, include rifapentine, levofloxacin, gatifloxacin and moxifloxacin. Recently there has been much development in the molecular pharmacology of anti-tuberculosis drugs. This review summarizes information for isoniazid, rifampicin, ethambutol, pyrazinamide, and fluoroquinolones, and describes their resistance mechanisms.
Export Options
About this article
Cite this article as:
Shi Ruiru, Itagaki Nobunori and Sugawara Isamu, Overview of Anti-Tuberculosis (TB) Drugs and Their Resistance Mechanisms, Mini-Reviews in Medicinal Chemistry 2007; 7 (11) . https://dx.doi.org/10.2174/138955707782331740
DOI https://dx.doi.org/10.2174/138955707782331740 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Progress on the Discovery of Inhibitors of InhA, the FAS II Enoyl-ACP Reductase TB Drug Discovery Targeted on InhA
Letters in Drug Design & Discovery Trends and Economic Stress: A Challenge to Universal Access to Antiretroviral Treatment in India
Current HIV Research Immune Modulation by Regulatory T Cells in Helicobacter pylori-Associated Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti Citrullinated Protein Antibodies and Mechanism of Action of Common Disease Modifying Drugs - Insights in Pathomechanisms of Autoimmunity
Current Pharmaceutical Design Antimycobacterial Activity: Synthesis and Biological Evaluation of Novel Substituted (3E,5E)-3,5-diarylidene-1-phenethylpiperidine-4-one Derivatives
Letters in Drug Design & Discovery Polymorphisms of Human N-Acetyltransferases and Cancer Risk
Current Drug Metabolism The Role of Hyphenated Chromatography-Mass Spectrometry Techniques in Exploratory Drug Metabolism and Pharmacokinetics
Current Pharmaceutical Design Vitamin, Mineral, and Drug Absorption Following Bariatric Surgery
Current Drug Metabolism Editorial [ Hot Topic: Drug-Resistant Tuberculosis - A Challenge in Chemotherapy (Guest Editor: Iwao Ojima) ]
Current Topics in Medicinal Chemistry Anti-Tubercular Agents from <i>Glycyrrhiza</i> glabra
Current Topics in Medicinal Chemistry Randomized Clinical Trials in Children - Ethical and Methodological Issues
Current Pharmaceutical Design Impact of Mast Cell Chymase on Renal Disease Progression
Current Hypertension Reviews Prioritizing Disease Genes by Using Search Engine Algorithm
Current Bioinformatics Using NMR to Develop New Allosteric and Allo-Network Drugs
Current Drug Discovery Technologies Regulation of ABC Transporter Function Via Phosphorylation by Protein Kinases
Current Pharmaceutical Biotechnology Adverse Drug Reactions to Anti-TB Drugs: Pharmacogenomics Perspective for Identification of Host Genetic Markers
Current Drug Metabolism The Balancing Act between Colonisers and Inflammation: T regulatory and TH17 Cells in Mucosal Immunity during Otitis Media
Current Immunology Reviews (Discontinued) Protein Microarrays for Studies of Drug Mechanisms and Biomarker Discovery in the Era of Systems Biology
Current Pharmaceutical Design New Strategies and Paradigm for Drug Target Discovery: A Special Focus on Infectious Diseases Tuberculosis, Malaria, Leishmaniasis, Trypanosomiasis and Gastritis
Infectious Disorders - Drug Targets Nanomedicine: Potential Devices for Diagnostics
Recent Patents on Nanomedicine